Lonza Group AG (LZAGF) is a publicly traded company in the Healthcare sector, operating within the Medical - Diagnostics & Research industry. The company is headquartered in Basel, Switzerland. The current CEO is Wolfgang Wienand.
LZAGF has IPO date of 2009-02-13, 17,995 full-time employees, listed on the Other OTC, a market capitalization of $48.28B.
Lonza Group AG is a global pharmaceutical and biotechnology services company headquartered in Basel, Switzerland, serving customers across Europe, the Americas, Asia, and the Pacific region. Operating through four main segments—Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients—the company provides contract development and manufacturing services for biopharmaceuticals, small molecule drugs, cell and gene therapies, and pharmaceutical ingredients. Its Biologics segment handles drug substance and product manufacturing throughout the product lifecycle, while the Small Molecules segment delivers integrated development and manufacturing for small molecule therapeutics. The Cell & Gene segment specializes in industrializing manufacturing processes for cell therapies, gene therapies, and exosome-based therapies, alongside specialty raw materials and enabling technologies. Founded in 1897, Lonza combines over a century of industry expertise with advanced manufacturing capabilities to support pharmaceutical, biotech, and nutrition markets worldwide.
